
Cooper Companies (COO) Stock Forecast & Price Target
Cooper Companies (COO) Analyst Ratings
Bulls say
Cooper Companies is supported by a durable position in eyecare and women’s health, with CooperVision’s roughly one-fourth share of the US contact lens market and CooperSurgical’s broad IVF and IUD exposure providing recurring demand and diversified growth drivers. The company has also shown it can translate that franchise strength into improved profitability, with recent revenue of $1.082B up 5% organic, adjusted EPS of $1.21 above consensus, and operating margin expanding to 26.3% as SG&A and R&D leverage improved. Looking ahead, management’s mid-single-digit organic revenue outlook, higher FCF guidance of $650M, and potential share repurchases or strategic actions around CSI reinforce a path to high-single-digit or better EPS growth.
Bears say
Cooper Companies is facing a weaker fundamental setup as revenue missed consensus at $1.066B and management cut FY26 guidance to $4.229-4.252B, with EPS outlook reduced to $4.51-$4.55. CooperVision, the key growth engine, slowed to 0% organic growth, missed consensus, and appears pressured by US channel inventory de-stocking of about $20M plus continued APAC weakness and legacy hydrogel declines, implying further share loss. Even with solid products and a broad portfolio, the combination of slower contact lens demand, lower FY26 expectations, and a rising FY27 tax rate to 17.5% supports a cautious, negative outlook.
This aggregate rating is based on analysts' research of Cooper Companies and is not a guaranteed prediction by Public.com or investment advice.
Cooper Companies (COO) Analyst Forecast & Price Prediction
Start investing in Cooper Companies (COO)
Order type
Buy in
Order amount
Est. shares
0 shares